We show that VEGFR2 activity on myeloid cells mediates immunosuppression and that inhibition of VEGFR2 signaling results in reduction of PD-L1 expression on myeloid cells and contributes to reinvigorated T cell activation in the tumor microenvironment, which improves response to ICI. The gene discussed is KDR; the disease is neoplasm.